Myriad
Myriad Genetics Reports 15 Percent Q2 Revenue Spike, Raises Full-Year Guidance
Myriad's total revenue grew 15 percent year over year, driven by growth in prenatal, pharmacogenomics, and hereditary cancer tests.
People in the News at Oxford Nanopore Technologies, Standard BioTools, Myriad Genetics
Recently posted executive and academic appointments, promotions, and departures in omics and molecular diagnostics.
Eurobio Scientific Acquires EndoPredict, Licenses Prolaris ex-US from Myriad Genetics
Myriad retained the rights to produce and sell EndoPredict in the US as part of its Precise Oncology Solutions platform.
Myriad Genetics, Personalis Cross-License MRD Technology
The companies inked an agreement to co-license their minimal residual disease technology in an effort to broaden testing access and boost adoption.
Myriad Genetics, GSK Collaborate on International Ovarian Cancer Testing Program
GSK will provide financial support for a program to expand access to Myriad's MyChoice tests for patients with high-grade serous ovarian cancer.